Bicara Therapeutics Inc. Common Stock (BCAX)

Bicara Therapeutics’ second fiscal quarter of 2026 results pointed to wider year-over-year losses, based on preliminary figures released August 11, 2026. GAAP net income was a loss of about $55.4 million, down 102.4% from a loss of roughly $27.4 million a year ago, while EPS came in at -$0.82 versus -$0.50 a year earlier (down 64.0%). The company reported GAAP operating income of about -$60.0 million, consistent with its profile as a clinical-stage biotechnology developer focused on solid-tumor therapies such as ficerafusp alfa. Cash use also remained elevated, with negative operating cash flow of roughly $44.2 million in the quarter. For the next period, consensus calls for EPS of -$0.85.